Users Online: 765
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
DRUG REVIEW
Year : 2015  |  Volume : 4  |  Issue : 1  |  Page : 38-40

Novel formulation of cytarabine and daunorubicin: A new hope in AML treatment


Department of Medicine, Leukemia/BMT Division, Vancouver General Hospital, Vancouver, British Columbia, Canada

Correspondence Address:
Lalit S Raut
Department of Medicine, Leukemia/BMT Division, Vancouver General Hospital, Vancouver, British Columbia
Canada
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2278-330X.149950

Rights and Permissions

Acute myeloid leukemia (AML) treatment has always been a challenge to the treating physician. Continuous efforts are being made to improve treatment outcomes in AML. CPX-351 is a pharmacologic advancement in this direction. It is a liposomal fixed drug combination of cytarabine and daunorubicin. Early studies indicate that it will play a big role in AML treatment. This is a short review about this drug.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2151    
    Printed95    
    Emailed0    
    PDF Downloaded480    
    Comments [Add]    
    Cited by others 10    

Recommend this journal